Kenya will begin rolling out long-acting injectable antiretroviral therapy next year and introduce twice-yearly lenacapavir shots as an additional prevention option for people at high risk, officials said, as the country grapples with a worrying rise in new infections. The new HIV treatment move aims to improve adherence and reduce the lifecycle costs of care for the roughly 1.3 million Kenyans living with HIV, but it arrives amid acute financing pressures for the broader health system.
Is There A Rise In HIV Infections In Kenya?
Official data released by the government on World AIDS Day show a sharp uptick in new infections: 19,991 new HIV cases were recorded in the last year, a 19 percent rise from the previous reporting period, with young people aged 15–34 accounting for the largest share of new infections. Nairobi County recorded the highest number of fresh cases, contributing more than 3,000 of the total. Health officials and advocates attribute the rebound to gaps in prevention, low testing rates, and interruptions in donor support for community programmes.
A new generation of HIV treatment in Kenya, and prevention tools, is central to the government’s response. Long-acting injectable antiretroviral therapy (LA-ART) — which replaces daily pills with injections at multi-week intervals, has been shown in multiple trials to boost viral suppression by removing the daily pill-taking barrier for people who struggle with adherence. Separately, lenacapavir (marketed as Yeztugo in some markets), a capsid-inhibitor formulated as a twice-yearly injectable for pre-exposure prophylaxis (PrEP), has been recommended by the World Health Organization and approved by regulators such as the US FDA as an additional prevention tool. Trials reported near-complete protection when administered on schedule.
Are Injectibles Effective In HIV Treatment?
Health ministry planners say the injectable options will be rolled out in phases, prioritising urban hotspots and high-risk cohorts, including key populations and young people, while integrating the new products with community testing, adherence support and differentiated service delivery models. Officials argue the programmatic shift is necessary: injectable options reduce reliance on daily dosing and clinic visits for prescription refills, potentially lowering long-term program costs caused by HIV treatment failure, hospital admissions and onward transmission.
But moving to injectables is not only a clinical question. Financing is a critical constraint. Prime Cabinet Secretary Musalia Mudavadi said Kenya needs about KSh 30 billion to secure essential prevention, HIV treatment and long-term care commodities for the national HIV response, noting the country currently supports more than 1.32 million people on HIV treatment. Domestic budgets, the government warns, must bridge gaps left by unpredictable donor flows if the new technologies are to reach scale.
Why Is SHA Struggling To Provide Health Cover?
The timing compounds pressures on the Social Health Authority (SHA), the state body managing expanded public insurance and benefits. In recent weeks SHA and the health ministry have moved to expand oncology benefits, raising the cancer care package, to reduce out-of-pocket costs for patients. Yet cancer care remains expensive and resource-intensive, and officials acknowledge the authority is being asked to shoulder major burdens at a time when HIV commodity financing also requires a boost. That trade-off raises real policy choices about how to prioritise scarce public funds across high-cost chronic conditions.
Public-health experts welcomed the injectables on clinical grounds but cautioned that new tools alone will not reverse the rising tide of infections. “Long-acting antiretrovirals and lenacapavir are transformative because they directly tackle adherence and reduce the frequency of contact required,” said an independent HIV researcher. “But to protect adolescents and young adults we also need to scale testing, keep prevention services accessible, and fund community organisations that reach marginalised groups.” Implementation must address cold-chain logistics, provider training, and systems to track timely re-injection, all elements that carry operational cost.
Are Young People At Risk of HIV Infection?
Epidemiological context makes speed and coverage especially important. Young people aged 15–34 now represent more than half of new infections in Kenya, a demographic reality that shifts the epidemic’s social and economic cost. For a country that has achieved high antiretroviral therapy (ART) coverage, official figures cited that roughly 87 percent of people living with HIV are on ART and prevention of mother-to-child transmission coverage exceeds 90 percent, the resurgence in new infections is a reminder that supply-side success must be matched by demand-side outreach and sustained prevention investment.
There are also equity and access questions. Lenacapavir’s rapid regulatory approvals internationally have stimulated global interest, but access in low- and middle-income countries depends on licensing, price negotiations, and donor or domestic procurement decisions. Civil society groups have urged governments to ensure the drug is affordable and available through public programmes; otherwise, the technology risks widening inequalities where wealthier or urban populations gain early access while rural or poorer groups fall further behind.
For the SHA, which is simultaneously expanding cancer packages and absorbing the responsibilities of a restructured national insurance system, the policy dilemma is stark. Oncology treatments can rapidly exhaust benefit limits even as HIV commodities require predictable, recurring procurement. Health economists say the solution lies in better priority-setting, pooled procurement of high-cost drugs, stronger public-private partnerships, and ringfenced financing for essential HIV commodities to avoid interruptions that would undermine decades of progress.
Targeted Communication Campaigns To Reach Key Populations
What the public can expect next: rollout pilots, national guidance and funding allocations. The ministry has committed to phased introduction, with targeted communication campaigns to reach youth and key populations, clinic readiness assessments, and collaboration with partners to secure supplies. But the scale of the 30-billion shilling financing gap suggests tough budget choices ahead, and a need for renewed donor engagement and inventive domestic financing mechanisms if Kenya is to make the most of promising new HIV treatment without compromising care for other major illnesses such as cancer.
As Kenya prepares to add injectables to its HIV treatment toolbox, the key test will be whether policymakers can translate scientific breakthroughs into accessible, affordable programmes that reach the young people driving the epidemic, while protecting gains in other health priorities. In a country where health budgets are being stretched, the promise of better adherence and simpler prevention is real; converting that promise into population-level impact will depend on money, logistics, and political will.
ALSO READ: The Nairobi Hospital Launches Home Blood Collection Service to Revolutionize Patient Care
